Starry Gene key facts
as of Oct 2026- Developer of genetic modification technologies intended for therapeutic applications in ophthalmic disorders.
- Starry Gene is valued at approximately $11.9M as of Oct 2026 (last reported valuation).
- It has raised $4.5M; the latest was Later Stage VC in Sep 2025.
- Notable investors include CAS Star, Hefei Industry Investment Group, Hefei Innovation Technology Venture Capital, Hefei Hi-Tech VC, Co-Win Ventures — 10 tracked in total.
- Status: Privately Held (backing).
Starry Gene's last reported valuation, Nov 2020. Nothing priced has surfaced since.
- ·Watch Starry Gene: the Monday email on marks, rounds and moves
Starry Gene funding rounds
No funding rounds for Starry Gene are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Starry Gene valuation
Starry Gene's last reported valuation was $11.9 million in Nov 2020. No priced round, secondary trade or fund mark has surfaced since.
Starry Gene investors
10 investors are on record for Starry Gene, including CAS Star, Hefei Industry Investment Group, Hefei Innovation Technology Venture Capital and Hefei Hi-Tech VC.
About Starry Gene
Developer of genetic modification technologies intended for therapeutic applications in ophthalmic disorders. The company focuses on the development of gene therapy drugs for ophthalmic diseases and the research and development of gene editing technology and services, serving clinical researchers and healthcare providers to access targeted, long-acting gene therapies that reduce treatment frequency and improve precision in managing degenerative eye conditions.
- Sector
- Healthcare
- HQ
- Hefei, China
- Founded
- 2019
- Employees
- 2
- Website
- starrygene.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.